Summary
The University of Oslo is inviting applications for a full-time PhD position in the Innate Lymphocyte Group, focusing on innovative research in pharmacology.
PhD Research Fellow in Pharmacology,University of Oslo, Norway
Designation
PhD Research Fellow
Table of Key Information
| Category | Details |
|---|---|
| Research Area | Pharmacology, Immunology, Cell Biology, Biochemistry |
| Location | Department of Pharmacology, Institute of Clinical Medicine, Oslo |
| Eligibility/Qualification | MSc degree in immunology, cell biology, or biochemistry |
| Last Date to Apply | 30th March 2026 |
Research Area
The focus of the research will be on overcoming cell membrane barriers using peptides, the targeted delivery of therapeutic molecules, and exploring synergistic effects with small molecule therapeutics.
Location
Department of Pharmacology, Rikshospitalet, Oslo, with a move to the new Life Sciences Building in 2027.
Eligibility/Qualification
- MSc degree within the fields of immunology, cell biology, or biochemistry.
- Excellent written and oral communication skills in English.
- Ability to teach in a Scandinavian language.
- Experience in extracellular vesicles, lipid nanoparticles, and confocal microscopy is advantageous.
Description
The successful candidate will develop realistic model membranes in the form of lipid nanoparticles and incorporate cell-penetrable peptides for precise delivery to cancer cells. The project will also involve designing antibiotic delivery systems aimed at bacterial membranes. Candidates should be prepared to collaborate with national and international partners and may need to travel. Responsibilities will include teaching, supervision, and research assistance.
How to Apply
Interested candidates should submit:
- Application letter
- CV
- Complete list of publications
- Transcripts and certificates
- Contact information for 2-3 references
Applications must be made through the University of Oslo’s recruitment system Jobbnorge.
Last Date to Apply
All applications must be submitted by 30th March 2026.
